ASLAN Pharmaceuticals, a biotech company focused on the development of immunotherapies and targeted agents for Asia-prevalent tumour types, has announced its move to a new office in Taiwan with immediate effect.
The new location will allow ASLAN to support its growing business in Taiwan and the Asia region, further strengthening the company’s capabilities and local presence.
Dr Carl Firth, CEO of ASLAN Pharmaceuticals, said: “ASLAN is strongly committed to its business in Taiwan. With a growing presence, we look forward to continue contributing to the local biotech industry as well as working with clinicians and patients in the country.”
The Taiwan office is one of three regional offices in Asia Pacific that drives ASLAN’s clinical development strategy in the region. ASLAN has operational presence in Singapore, China and Australia.